BackEver Supreme Bio Technology , Ltd Overview

Ever Supreme Bio Technology , Ltd Long Term Debt

Ever Supreme Bio Technology , Ltd's long-term debt is $23M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$23.00M
↓ 31.49% YoYΔ $-10.58M vs prior year quarter

Peer trimmed avg / median

Loading

Ever Supreme Bio Technology , Ltd Long Term Debt History

Loading

Ever Supreme Bio Technology , Ltd vs. peers: Long Term Debt Comparison

Loading

Ever Supreme Bio Technology , Ltd Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ever Supreme Bio Technology , Ltd (6712.TWO) FAQ

Ever Supreme Bio Technology , Ltd posts a long-term debt of $23M as of June 2026. That compares with $34M in the prior-year period — down 31.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Ever Supreme Bio Technology , Ltd's long-term debt was $34M. The latest reading is $23M — a 31.5% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Ever Supreme Bio Technology , Ltd's financial statement story. At $23M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 6712.TWO's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Ever Supreme Bio Technology , Ltd's other metric pages and overview cover the third.

Judging Ever Supreme Bio Technology , Ltd against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $23M here, then scan peer and history charts to see if the gap is persistent.